ALKS Alkermes plc
Alkermes plc (ALKS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 47% planned / 53% discretionary
Largest single sale: $2.2M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $48.01 | $97.7K | 223,422 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $46.99 | $422.9K | 65,389 −12.1% of holding | |
| Nichols Christian Todd 2 fills | SVP, Chief Commercial Officer | Sell 10b5-1 | 7,576 | $49.23 | $372.9K | 102,857 −6.9% of holding | |
| snyderman nancy lynn MD | Director | Sell | 44,472 | $50.35 | $2.2M | 15,395 −74.3% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $48.58 | $437.2K | 69,389 −11.5% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $48.58 | $98.8K | 225,456 −0.9% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $54.03 | $109.9K | 227,490 −0.9% of holding | |
| Hopkinson Craig C. 2 fills | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $51.51 | $463.6K | 74,089 −10.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.